FOXP3 and graft versus host disease: We saw a significant increase in FoxP3+ CD4+ T cells in GVHD patient primary cells treated with SLP76pTYR peptide, and a trend towards increased production in healthy human treated cells (Figure 8A,B; Figure S7A).